FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947906025> ?p ?o ?g. }

• W2947906025 endingPage "426" @default.
• W2947906025 startingPage "418" @default.
• W2947906025 abstract "Dupilumab is the first biologic registered for the treatment of moderate‐to‐severe atopic dermatitis (AD), and efficacy was shown in phase III clinical trials (primary outcome at week 16 was reached in 38% of patients). Currently, there are limited daily practice data available for dupilumab, especially when it is combined with systemic immunosuppressants. To evaluate dupilumab treatment in daily practice in patients with AD. In this observational cohort study, we prospectively included all adult patients with AD who had been treated with dupilumab in two university hospitals in the Netherlands. Concomitant systemic immunosuppressive treatment was monitored. Physician‐reported outcome measures and patient‐reported outcome measures (PROMs) after ≥ 12 weeks of follow‐up were analysed. We used a linear mixed‐effects model to determine changes in scores during follow‐up. Ninety‐five patients were included. Of these, 62 patients were using systemic immunosuppressants at baseline; the use of systemic immunosuppressants was continued during dupilumab treatment in 43 patients. From baseline to 16 weeks of treatment, the estimated mean Eczema Area and Severity Index score (0–72) decreased from 18·6 [95% confidence interval (CI) 16·0–21·4)] to 7·3 (95% CI 5·4–10·0), and the estimated mean PROMs showed a decrease of 41–66%. Investigator's Global Assessment 0 or 1 (clear/almost clear) was reached in 38% of the patients. Five patients discontinued dupilumab treatment due to side‐effects or ineffectiveness. Eye symptoms and orofacial (nonocular) herpes simplex virus (HSV) reactivation were reported in 62% and 8% of the patients, respectively. Dupilumab treatment in daily practice shows a clinically relevant improvement of physician‐reported outcome measures and PROMs, which is in line with efficacy data from clinical trials. Besides frequently reported eye symptoms and orofacial (nonocular) HSV reactivation, there were no apparent safety concerns. What's already known about this topic? Dupilumab has been shown to be an efficacious treatment for atopic dermatitis in several clinical trials. However, it is known that there may be considerable differences in patient characteristics and treatment responses between clinical trials and daily practice. What does this study add? This study presents the first experience with dupilumab treatment in 95 patients with atopic dermatitis in daily practice in two Dutch university hospitals. Less stringent inclusion and exclusion criteria and follow‐up schedules, in contrast to those used in clinical trials, might better represent daily practice. Dupilumab treatment shows a clinically relevant improvement of physician‐ and patient‐reported outcome measures; besides patient‐reported eye symptoms (in 59 of 95 patients; 62%) and an apparent increase in orofacial (nonocular) herpes simplex virus reactivation (eight of 95 patients; 8%), there were no other safety concerns during follow‐up up to 16 weeks of dupilumab treatment." @default.
• W2947906025 created "2019-06-07" @default.
• W2947906025 creator A5003599279 @default.
• W2947906025 creator A5004775387 @default.
• W2947906025 creator A5028977769 @default.
• W2947906025 creator A5051679049 @default.
• W2947906025 creator A5052925184 @default.
• W2947906025 creator A5072786878 @default.
• W2947906025 creator A5079222405 @default.
• W2947906025 creator A5079589294 @default.
• W2947906025 creator A5086168189 @default.
• W2947906025 creator A5089616935 @default.
• W2947906025 date "2019-10-16" @default.
• W2947906025 modified "2023-10-07" @default.
• W2947906025 title "Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data" @default.
• W2947906025 cites W1583257755 @default.
• W2947906025 cites W2029005903 @default.
• W2947906025 cites W2038882458 @default.
• W2947906025 cites W2058562555 @default.
• W2947906025 cites W2071937455 @default.
• W2947906025 cites W2096991001 @default.
• W2947906025 cites W2109260550 @default.
• W2947906025 cites W2117359358 @default.
• W2947906025 cites W2120793327 @default.
• W2947906025 cites W2137991831 @default.
• W2947906025 cites W2147391287 @default.
• W2947906025 cites W2192134383 @default.
• W2947906025 cites W2524051065 @default.
• W2947906025 cites W2557191479 @default.
• W2947906025 cites W2620177205 @default.
• W2947906025 cites W2623694744 @default.
• W2947906025 cites W2744776760 @default.
• W2947906025 cites W2751469248 @default.
• W2947906025 cites W2769186748 @default.
• W2947906025 cites W2793961807 @default.
• W2947906025 cites W2801208468 @default.
• W2947906025 cites W2802952796 @default.
• W2947906025 cites W2804940047 @default.
• W2947906025 cites W2883685466 @default.
• W2947906025 cites W2888908499 @default.
• W2947906025 cites W2889194084 @default.
• W2947906025 cites W2896868681 @default.
• W2947906025 cites W2909569977 @default.
• W2947906025 cites W2912193282 @default.
• W2947906025 cites W2916087813 @default.
• W2947906025 cites W2936340152 @default.
• W2947906025 cites W2936645347 @default.
• W2947906025 cites W2941471437 @default.
• W2947906025 cites W2944522746 @default.
• W2947906025 cites W3022423927 @default.
• W2947906025 cites W4210971299 @default.
• W2947906025 cites W4211052952 @default.
• W2947906025 cites W4211145137 @default.
• W2947906025 cites W4249094496 @default.
• W2947906025 doi "https://doi.org/10.1111/bjd.18179" @default.
• W2947906025 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31145810" @default.
• W2947906025 hasPublicationYear "2019" @default.
• W2947906025 type Work @default.
• W2947906025 sameAs 2947906025 @default.
• W2947906025 citedByCount "56" @default.
• W2947906025 countsByYear W29479060252019 @default.
• W2947906025 countsByYear W29479060252020 @default.
• W2947906025 countsByYear W29479060252021 @default.
• W2947906025 countsByYear W29479060252022 @default.
• W2947906025 countsByYear W29479060252023 @default.
• W2947906025 crossrefType "journal-article" @default.
• W2947906025 hasAuthorship W2947906025A5003599279 @default.
• W2947906025 hasAuthorship W2947906025A5004775387 @default.
• W2947906025 hasAuthorship W2947906025A5028977769 @default.
• W2947906025 hasAuthorship W2947906025A5051679049 @default.
• W2947906025 hasAuthorship W2947906025A5052925184 @default.
• W2947906025 hasAuthorship W2947906025A5072786878 @default.
• W2947906025 hasAuthorship W2947906025A5079222405 @default.
• W2947906025 hasAuthorship W2947906025A5079589294 @default.
• W2947906025 hasAuthorship W2947906025A5086168189 @default.
• W2947906025 hasAuthorship W2947906025A5089616935 @default.
• W2947906025 hasBestOaLocation W29479060251 @default.
• W2947906025 hasConcept C126322002 @default.
• W2947906025 hasConcept C16005928 @default.
• W2947906025 hasConcept C205545832 @default.
• W2947906025 hasConcept C23131810 @default.
• W2947906025 hasConcept C2776173921 @default.
• W2947906025 hasConcept C2778329239 @default.
• W2947906025 hasConcept C2779384505 @default.
• W2947906025 hasConcept C2779824493 @default.
• W2947906025 hasConcept C2780564577 @default.
• W2947906025 hasConcept C2780699399 @default.
• W2947906025 hasConcept C30036603 @default.
• W2947906025 hasConcept C44249647 @default.
• W2947906025 hasConcept C71924100 @default.
• W2947906025 hasConcept C72563966 @default.
• W2947906025 hasConceptScore W2947906025C126322002 @default.
• W2947906025 hasConceptScore W2947906025C16005928 @default.
• W2947906025 hasConceptScore W2947906025C205545832 @default.
• W2947906025 hasConceptScore W2947906025C23131810 @default.
• W2947906025 hasConceptScore W2947906025C2776173921 @default.
• W2947906025 hasConceptScore W2947906025C2778329239 @default.
• W2947906025 hasConceptScore W2947906025C2779384505 @default.

• next